Why the study?
Atrial fibrillation increases mortality and adverse outcomes, but its underlying molecular mechanisms remain largely unknown.
Multiomics approaches offer potential for discovering novel biomarkers to improve atrial fibrillation risk prediction and identify therapeutic targets.
Multiomics AF biomarkers remain hypothesis-generating; leaves open validation before any role in risk scores or therapy.
Atrial fibrillation (AF) is a common cardiac arrhythmia leading to many adverse outcomes and increased mortality. Yet the molecular mechanisms underlying AF remain largely unknown. Recent advances in high-throughput technologies make large-scale molecular profiling possible. In the past decade, multiomics studies of AF have identified a number of potential biomarkers of AF. In this review, we focus on the studies of multiomics profiles with AF risk. We summarize recent advances in the discovery of novel biomarkers for AF through multiomics studies. We also discuss limitations and future directions in risk assessment and discovery of therapeutic targets for AF.
No takes yet. Share an insight, caveat, or question.
Kornej et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: